Poor
Misaligned
Patient Risk:
High
Summary
Substantial mismatch with the provided label excerpts, including material contradictions on quantitative adverse reaction rates (injection-site reactions and constipation). Several efficacy/timing and administration-route claims are unsupported by the supplied label sections, and multiple non-label business/patent/pricing statements are unverifiable.
Category Scores
Accurate Statements
Aimovig blocks CGRP receptors involved in migraine pain.
Supported by 12.1: binds to the CGRP receptor and antagonizes CGRP receptor function.
Aimovig targets calcitonin gene-related peptide (CGRP).
Supported by 12.1: binds to the calcitonin gene-related peptide (CGRP) receptor.
Aimovig is FDA-approved only for episodic or chronic migraines.
Supported in concept by 1 (preventive treatment of migraine in adults) and 14 describing efficacy studies in episodic and chronic migraine populations.
Serious risks of Aimovig include allergic reactions.
Supported by 5.1 (hypersensitivity reactions including rash/angioedema/anaphylaxis) and 6 (serious adverse reactions list includes hypersensitivity reactions).
Serious risks of Aimovig include high blood pressure.
Supported by 5.3 (hypertension) and 6 (serious adverse reactions list includes hypertension).
Unsupported Statements
Aimovig reduces the frequency of migraine attacks.
No efficacy/frequency-reduction results are present in the provided label excerpts (14 excerpt is study description only).
CGRP triggers migraines.
No such statement appears in the provided label excerpts.
Patients inject Aimovig monthly under the skin.
The provided excerpts do not explicitly state route (subcutaneous) or administration instructions; only 'once monthly' dosing is indirectly reflected (e.g., 6.1 mentions once monthly dosing amounts).
Patients typically see fewer migraine days after 1-3 months of Aimovig.
The provided label excerpts do not include efficacy timing/results; only adverse-reaction timing (first 3 months) is shown in 6.1.
Aimovig is not indicated for tension headaches.
No explicit non-indication language for tension headaches is present in the provided label excerpts.
Aimovig is not indicated for cluster headaches.
No explicit non-indication language for cluster headaches is present in the provided label excerpts.
Aimovig is not indicated for sinus headaches.
No explicit non-indication language for sinus headaches is present in the provided label excerpts.
Aimovig is FDA-approved for episodic or chronic migraines (4+ migraine days per month).
The provided excerpts define episodic migraine (4 to 14 migraine days/month) and chronic migraine in 14, but the specific approval wording '4+ migraine days per month' is not explicitly shown in the provided label text.
In trials, patients report 50% fewer migraine days on average with Aimovig.
No efficacy outcome percentages are present in the provided label excerpts.
Results with Aimovig vary.
No variability/distribution discussion appears in the provided label excerpts.
Aimovig was co-developed by Amgen and Novartis.
No developer/co-development information appears in the provided label excerpts.
The list price of Aimovig is about $800 per monthly dose.
No pricing information appears in the provided label excerpts.
Insurance often covers part of Aimovig.
No payer/coverage information appears in the provided label excerpts.
Copays for Aimovig can be $0-100 via savings cards.
No copay/savings card information appears in the provided label excerpts.
Key U.S. patents for Aimovig expire around 2031-2035.
Patent expiration information is not present in FDA prescribing information and is not in the provided excerpts.
Challenges to Aimovig patents from Teva and others are pending.
Patent litigation/challenge status is not present in the provided label excerpts.
No biosimilars for Aimovig are yet available.
Biosimilar availability status is not present in the provided label excerpts.
Aimovig (erenumab-aooe) treats migraine headaches in adults.
The label excerpt supports preventive treatment of migraine in adults (1), but the claim characterizes 'treats' (acute/relief) without label support in the provided sections.
Contradictions
High
AI Statement
Injection-site reactions (pain, redness) occur in 40-50% of users.
Label Reference
6.1 Table 1 (adverse reactions during first 3 months in Studies 1, 2, and 3): injection site reactions are 6% (70 mg), 5% (140 mg), 3% (placebo) in the provided excerpt; 40–50% is not supported and conflicts with the excerpted values.
High
AI Statement
Constipation affects 10-20% of users.
Label Reference
6.1 Table 1 (adverse reactions during first 3 months): constipation is 1% (70 mg), 3% (140 mg), 1% (placebo) in the provided excerpt; 10–20% is not supported and conflicts with the excerpted values.
Important Omissions
No statement in the provided extracted claims addresses contraindications, which are referenced by the warnings text (e.g., 5.1 referencing Contraindications).
Importance:
Moderate
No extracted claims included boxed warning content (if any) or other label warnings/precautions beyond hypersensitivity, constipation complications, and hypertension.
Importance:
Moderate
No extracted claims included monitoring recommendations language (e.g., monitoring for new-onset/worsening hypertension; monitoring/managing severe constipation) despite these being explicit in the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Quantitative adverse reaction rates are materially contradicted (injection-site reactions and constipation), which could mislead safety burden assessment. Multiple administration/efficacy-timing claims are unsupported by provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Misaligned
Primary Issue
Material contradictions in quantitative adverse reaction rates (40–50% injection-site reactions; 10–20% constipation) versus provided label excerpted values (~3–6% and 1–3% respectively).
Suggested Improvement
Remove or replace unsupported/contradicted quantitative claims with label-supported incidence ranges from 6.1 Table 1, and avoid asserting efficacy timing/magnitude or administration route unless explicitly supported by the provided label sections.